Interleukin-1 family cytokines and mast cells: Activation and inhibition

Journal of Biological Regulators and Homeostatic Agents

Volumn 33, Issue 1, 2019, Pages 1-6

  Gallenga, C E ^a   Pandolfi, F ^b   Caraffa, A ^c   Kritas, S K ^d   Ronconi, G ^e   Toniato, E ^f   Martinotti, S ^f   Conti, Pio ^f  

^a UNIVERSITY OF FERRARA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF CAMERINO   (Italy)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^f UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cytokine; Inflammation; Inhibition; Interleukin; Mast cell

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 33; INTERLEUKIN 36; INTERLEUKIN 37; INTERLEUKIN 38; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; INFLAMMATION; MAST CELL; NONHUMAN; THERAPY EFFECT;

EID: 85061661004     PISSN: 0393974X     EISSN: 17246083     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Galli SJ, Kalesnikoff J, Grimbaldeston MA, et al. Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005; 23:749-86. Review.
2. Conti P, Lessiani G, Kritas SK, Ronconi G, Caraffa A, Theoharides TC. Mast cells emerge as mediators of atherosclerosis: Special emphasis on IL-37 inhibition. Tissue Cell 2017; 49(3):393-400.
3. Taracanova A, Tsilioni I, Conti P, Norwitz ER, Leeman SE, Theoharides TC. Substance P and IL-33 administered together stimulate a marked secretion of IL-1β from human mast cells, inhibited by methoxyluteolin. Proc Natl Acad Sci U S A 2018; 115(40):E9381-E9390.
4. Conti P, D’Ovidio C, Conti C, et al. Progression in migraine: Role of mast cells and pro-inflammatory and anti-inflammatory cytokines. Eur J Pharmacol 2018; 844:87-94.
5. Conti P, Carinci F, Caraffa A, et al. Link between mast cells and bacteria: Antimicrobial defense, function and regulation by cytokines. Med Hypotheses 2017; 106:10-14.
6. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27:519-50.
7. Tettamanti L, Kritas SK, Gallenga CE, et al. IL- 33 mediates allergy through mast cell activation: Potential inhibitory effect of certain cytokines. J Biol Regul Homeost Agents 2018; 32(5):1061-65.
8. Conti P, Caraffa A, Mastrangelo F, et al. Critical role of inflammatory mast cell in fibrosis: Potential therapeutic effect of IL-37. Cell Prolif 2018; 51(5):e12475.
9. Conti P, Caraffa A, Ronconi G, et al. Mast cells participate in allograft rejection: can IL-37 play an inhibitory role? Inflamm Res 2018; 67(9):747-55.
10. Conti P, Tettamanti L, Mastrangelo F, et al. Impact of fungi on immune responses. Clin Ther 2018; 40(6):885-88.
11. Cavalli G, Dinarello CA. Suppression of inflammation and acquired immunity by IL-37. Immunol Rev 2018; 281(1):179-90.
12. Cayrol C, Girard JP. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. Immunol Rev 2018; 281(1):154-68.
13. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity 2013; 39(6):1003-18.
14. Caraffa A, Conti C, D Ovidio C, et al. New concepts in neuroinflammation: mast cells pro-inflammatory and anti-inflammatory cytokine mediators. J Biol Regul Homeost Agents 2018; 32(3):449-54.
15. Conti P, Ronconi G, Kritas SK, Caraffa A, Theoharides TC. Activated mast cells mediate low-grade inflammation in Type 2 Diabetes: Interleukin-37 Could Be Beneficial. Can J Diabetes 2018; 42(5):568-73.
16. Coll-Miró M, Francos-Quijorna I, Santos-Nogueira E,et al. Beneficial effects of IL-37 after spinal cord injury in mice. Proc Natl Acad Sci U S A. 2016; 113(5):1411-16.
17. Conti P, Caraffa A, Ronconi G, et al. Impact of mast cells in mucosal immunity of intestinal inflammation: Inhibitory effect of IL-37. Eur J Pharmacol 2018; 818:294-99.
18. Conti P, Carinci F, Lessiani G, et al. Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells. Immunol Res 2017;65(5):982-86.
19. Luo Y, Cai X, Liu S, et al. Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci U S A 2014; 111(42):15178-83.
20. Varvara G, Tettamanti L, Gallenga CE, Caraffa A, D’Ovidio C, Mastrangelo F, Ronconi G, Kritas SK, Conti P. Stimulated mast cells release inflammatory cytokines: potential suppression and therapeutical aspects. J Biol Regul Homeost Agents 2018; 32(6):1355-60.
21. van de Veerdonk FL, Stoeckman AK, Wu G, Boeckermann AN, Azam T, Netea MG, Joosten LA, van der Meer JW, Hao R, Kalabokis V, Dinarello CA. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci U S A 2012; 109(8):3001-5.
22. van de Veerdonk FL, de Graaf DM, Joosten LA, Dinarello CA. Biology of IL-38 and its role in disease. Immunol Rev 2018; 281(1):191-96.